KLOX Technologies reports on its interim results from its ongoing clinical studies on LumiHeal(TM) for the treatment of chronic wounds and postsurgical scarring

Data presented at the 2016 World Union of Wound Healing Societies Congress

LAVAL, Quebec, Sept. 28, 2016 (GLOBE NEWSWIRE) -- Today, clinical interim results on KLOX Technologies (Klox) LumiHeal^TM for the treatment of hard-to-heal non-responsive chronic wounds and postsurgical scarring will be reported in conjunction with the 2016 World Union of Wound Healing Societies (WUWHS) Congress in Florence, Italy.

The Klox LumiHeal^TM system is a first-in-class, proprietary, non-invasive, non-thermal treatment that harnesses the power of fluorescence in the presence of oxidants to treat serious skin and soft tissue disorders.

"We believe that LumiHeal^TM can really make a significant difference in the way we manage and treat acute and chronic wounds", stated Dr. Marco Romanelli, MD, PhD, Associate Professor of Dermatology at the School of Medicine, University of Pisa, and Chief of the Wound Healing Research Unit, and President Elect of the World Union of Wound Healing Societies. "This is an area where an unmet need remains, and with LumiHeal's^TMinnovative approach, excellent safety profile and effectiveness, it can help bridge that gap."

Professor Franco Bassetto, Head Clinic of Plastic Surgery Full Professor of Plastic Surgery Chair and Residency Program of Plastic Reconstructive and Aesthetic Surgery, University Hospital of Padova, Italy, will at 12:15 p.m. (CEST) unveil interim results from the EUREKA study, which evaluated the real-life use of LumiHeal^TM in chronic wounds management.

Following Professor Bassetto's presentation, Professor Andreas Nikolis, MD, MSc, FRCSC, Plastic Reconstructive and Aesthetic Surgery, Associate Professor of Plastic Surgery, Division of plastic surgery, University of Montreal, Canada, will share interim findings comparing LumiHeal^TM to silicone sheets in the treatment of surgical wounds in the context of breast reductions.

"We are thrilled by the interim results of both studies and the high level of satisfaction from patients and investigators. Due to its ease of use and effectiveness, 95% of investigators involved in the chronic wound management study, EUREKA, stated they would recommend LumiHeal^TM to their colleagues", said Dr. Michel Cimon, MD, Senior Vice President, Chief Medical and Science Officer of KLOX Technologies. "Furthermore, the vast majority of patients that completed the postsurgical scarring study to date, were more satisfied with the use of LumiHeal^TM with respect to ease of use and complexity of treatment."